Update on nonserous ovarian cancer trials.
نویسندگان
چکیده
There is consensus that two distinct histotypes of epithelial ovarian cancer, i.e. clear-cell carcinoma and mucinous adenocarcinoma, are more resistant to chemotherapy and have a worse prognosis than the papillary serous type [1, 2]. Therefore, gynecological trial groups have been conducting histotypespecific trials for these two entities. In this article, we discuss the updated status of trials that are ongoing, or being planned worldwide on nonserous ovarian cancer, in particular the clearcell carcinoma (CCC) and the mucinous adenocarcinomas of the ovary.
منابع مشابه
Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
PURPOSE Hallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and improved survival. The therapeutic impact of somatic BRCA1/2 mutations and mutations in other homologous recombination DNA repair genes is uncertain. EXPERIMENTAL DESIGN Using targeted capture and massively parallel genomic sequencing, we assessed 390 ovarian carcinomas for germline and somatic lo...
متن کاملCirculating Estrogens and Postmenopausal Ovarian Cancer Risk in the Women's Health Initiative Observational Study.
BACKGROUND Hormonal and reproductive factors contribute to the development of ovarian cancer, but few studies have examined associations between circulating estrogens and estrogen metabolites and ovarian cancer risk. We evaluated whether serum estrogens and estrogen metabolite levels are associated with ovarian cancer risk among postmenopausal women in a nested case-control study in the Women's...
متن کاملPredictive Biomarkers and Personalized Medicine Germline and Somatic Mutations in Homologous Recombination Genes Predict Platinum Response and Survival in Ovarian, Fallopian Tube, and Peritoneal Carcinomas
Purpose: Hallmarks of germline BRCA1/2-associated ovarian carcinomas include chemosensitivity and improved survival. The therapeutic impact of somatic BRCA1/2 mutations and mutations in other homologous recombination DNA repair genes is uncertain. Experimental Design: Using targeted capture and massively parallel genomic sequencing, we assessed 390ovarian carcinomas for germline and somatic los...
متن کاملDNA repair mutations and outcomes in ovarian cancer--response.
We appreciate the thoughtful comments from Dr. Soslow (1) and agree with many of his points. As he pointed out, many institutions reserve genetic testing for ovarian cancers with high-grade serous histology (2). We believe such a restriction in current practice is a mistake and will miss identifying carriers of mutations in BRCA1 and BRCA2 as well as other more recently identified ovarian cance...
متن کاملUpdate of randomized trials in recurrent disease.
In the absence of significant advance in first-line therapy until recently, the increased knowledge of how to manage relapse accounts for most of the advances observed in ovarian cancer during the last 10 years. In addition, a large number of new drugs, mostly in the category of 'targeted therapy', are currently being tested in the setting of recurrent ovarian and are expected to change the cou...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Annals of oncology : official journal of the European Society for Medical Oncology
دوره 24 Suppl 10 شماره
صفحات -
تاریخ انتشار 2013